Memphis, TN, United States of America

Veeresh Gududuru

This inventor holds 2 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 1 EPO patent. Top assignee: Rxbio, Inc.. Active years: 2014-2017.

USPTO Granted Patents = 2 

% Patents Active = 100.0


 

Average Co-Inventor Count = 1.8

ph-index = 1


Company Filing History:


Years Active: 2014-2017

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Veeresh Gududuru: Innovator in Pharmaceutical Chemistry

Introduction

Veeresh Gududuru is a notable inventor based in Memphis, TN (US). He has made significant contributions to the field of pharmaceutical chemistry, holding 2 patents that showcase his innovative spirit and dedication to advancing medical science.

Latest Patents

His latest patents include "Crystalline salts of (Z)-O-octadec-9-en-1-yl O,O-dihydrogen phosphorothioate," which describes a salt form of the compound with an L-lysine addition in crystalline form, along with methods for making and using it. Another patent, "LPA receptor agonists and antagonists," discloses compounds that have potential applications in treating cancer, enhancing cell proliferation, and preserving organ function, among other therapeutic uses.

Career Highlights

Veeresh is currently employed at Rxbio, Inc., where he continues to push the boundaries of pharmaceutical research. His work focuses on developing innovative solutions that can lead to improved health outcomes.

Collaborations

He collaborates with talented individuals such as Rama Krishna Reddy Singidi and Mahmoud Mirmehrabi, contributing to a dynamic research environment that fosters creativity and innovation.

Conclusion

Veeresh Gududuru's contributions to pharmaceutical chemistry through his patents and collaborative efforts highlight his role as a key innovator in the field. His work not only advances scientific knowledge but also has the potential to improve patient care and treatment options.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…